8-K

0000950170-23-000844.txt : 20230118 0000950170-23-000844.hdr.sgml : 20230118 20230118094725 ACCESSION NUMBER: 0000950170-23-000844 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230118 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230118 DATE AS OF CHANGE: 20230118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLASE, INC CENTRAL INDEX KEY: 0000811240 STANDARD INDUSTRIAL CLASSIFICATION: DENTAL EQUIPMENT & SUPPLIES [3843] IRS NUMBER: 870442441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36385 FILM NUMBER: 23533224 BUSINESS ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 BUSINESS PHONE: 949-361-1200 MAIL ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 FORMER COMPANY: FORMER CONFORMED NAME: BIOLASE TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER MEDICAL TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER ENDO TECHNIC CORP DATE OF NAME CHANGE: 19920708 8-K 1 biol-20230118.htm 8-K 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 18, 2023

BIOLASE, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-36385	87-0442441
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

27042 Towne Centre Drive, Suite 270
Lake Forest, California		92610
(Address of Principal Executive Offices)		(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 361-1200
Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

BIOL

The NASDAQ Stock Market LLC
(NASDAQ Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 18, 2023, BIOLASE, Inc. issued a press release announcing certain preliminary results for the fourth quarter and full year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

d) Exhibits.

The following exhibit is being furnished as part of this Current Report on Form 8-K:


Exhibit No.		Description
99.1		Press Release of BIOLASE dated January 18, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	BIOLASE, INC.

Date: January 18, 2023	By	/s/ JENNIFER BRIGHT
		Name: Jennifer Bright
		Title: Chief Financial Officer

EX-99.1 2 biol-ex99_1.htm EX-99.1 EX-99.1


	Exhibit 99.1

BIOLASE MAINTAINS POSITIVE MOMENTUM THROUGH YEAR END WITH SOLID FOURTH QUARTER REVENUE GROWTH; SIGNIFICANT MARKET OPPORTUNITY AND INDUSTRY-LEADING PRODUCT SUPPORT EXPECTATION FOR ROBUST REVENUE GROWTH IN 2023

Foothill Ranch, Calif., January 18, 2023 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that based on currently available information, preliminary 2022 fourth quarter revenue is expected to be between $14.0 million and $14.4 million, well above 2021 fourth quarter revenue of $12.4 million. The Company will report fourth quarter and full-year 2022 results in March 2023.

As demonstrated by its continued positive results, the Company believes it is well positioned with its industry-leading dental lasers, broad intellectual property ("IP") portfolio, and recently bolstered balance sheet to capitalize on the significant market opportunity for dental laser adoption.

Below are preliminary fourth quarter and full-year revenue results, a recap of the Company’s 2022 key accomplishments, and anticipated operational and product milestones for 2023.

Preliminary Fourth Quarter and Full-Year Results

•

Fourth quarter revenue is expected to be between $14.0 million and $14.4 million, reflecting a 13% to 16% increase over the fourth quarter of 2021

•

Full-year 2022 revenue is expected to be in the range of $48.4 million to $48.8 million, representing 24% to 25% growth over 2021

•

The Company generated increased adoption of its industry-leading laser with approximately 84% of U.S. Waterlase sales in the fourth quarter and full-year 2022 coming from new customers

•

The Company delivered an increased sales conversion rate throughout the year with the continued success of its Waterlase Exclusive Trial Program

2022 Accomplishments

•

Demonstrated leadership in creating awareness of the benefits of laser dentistry through over 600 webinars, study clubs, and training events in 2022

•

Waterlase delivered increased utilization rates with close to 70% of new customers using Waterlase daily, based on Company data

•

Achieved record consumable sales in 2022

•

Significantly improved its marketing engine in 2022 with marketing qualified leads increasing 4x over 2018 levels

•

Solidified its sales force with no turnover in 2022 and a fully staffed sales force with 25 territory managers entering 2023

•

Added new OEM revenue stream with EdgePro product launch through a partnership with EdgeEndo

•

Purchased supplier and IP for key manufacturing components

•

Appointed a new Chief Dental Officer who joined BIOLASE from Heartland Dental, the largest Dental Service Organization in the U.S.

Anticipated 2023 Milestones Expected to Position BIOLASE for Long-Term Growth and Success

In 2023, the Company plans to:

•

Achieve positive adjusted EBITDA results for the full year of 2023 (adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, patent litigation settlements, stock-based and other non-cash compensation, and the change in allowance for doubtful accounts)

•

Grow total full-year 2023 revenue by at least 25% through continued adoption of lasers and consumables by the dental community including general dentists, dental specialists, dental hygienists, and group practice entities (DSOs)

•

Expand OEM revenue base through its partnership with EdgeEndo

•

Broaden participation in BIOLASE dental and hygiene academies to expand awareness of the benefits of BIOLASE lasers to patients

•

Launch training centers to enhance sales and marketing efforts and communicate the benefits of BIOLASE technology

•

Expand the Waterlase Exclusive Trial Program to drive increased adoption

•

Open a model dental office to increase marketing, testimonial, and training opportunities

•

Expand the DSO customer base and further penetrate the DSO market

•

Realize cost savings and improve quality from in-house manufacturing of key components

•

Execute growth strategy with over $13.0 million in cash and cash equivalents, including net proceeds from its January 2023 equity raise

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 302 patented and 28 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems from 1998 through December 31, 2021 in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase®, and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's preliminary fourth quarter and full-year 2022 revenue, beliefs relating to BIOLASE’s ability to capitalize on the dental laser market opportunity, expected 2023 revenue growth, anticipated 2023 milestones and the expected effects, and BIOLASE’s plans for 2023. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Among other things, there can be no assurance that BIOLASE’s actual full-year 2022 financial and operating results will not differ, perhaps substantially, from the preliminary financial and operating results and expectations contained in this press release. In addition, BIOLASE has not completed its fourth quarter and full-year 2022 closing and review process, and the final results for the full-year 2022 may differ, perhaps substantially, from the statements made in this press release. During the course of preparing BIOLASE’s financial statements and during the review process, management may identify items that would require adjustments that may be material to the amounts described in this press release. Actual results may also differ materially from BIOLASE's current expectations depending upon a number of other factors. These factors

include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, substantial doubt regarding BIOLASE's ability to continue as a going concern, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report on Form 10-K and quarterly report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

EVC Group LLC

Michael Polyviou / Todd Kehrli

(732) 933-2754

mpolyviou@evcgroup.com / tkehrli@evcgroup.com

GRAPHIC 3 img239377025_0.jpg GRAPHIC begin 644 img239377025_0.jpg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

Document and Entity Information	Jan. 18, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 18, 2023
Trading Symbol	BIOL
Entity Registrant Name	BIOLASE, INC.
Entity Central Index Key	0000811240
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity File Number	001-36385
Entity Tax Identification Number	87-0442441
Entity Address, Address Line One	27042 Towne Centre Drive
Entity Address, Address Line Two	Suite 270
Entity Address, City or Town	Lake Forest
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92610
City Area Code	949
Local Phone Number	361-1200
Entity Incorporation, State or Country Code	DE
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false

XML 8 biol-20230118_htm.xml IDEA: XBRL DOCUMENT 0000811240 2023-01-18 2023-01-18 0000811240 false 8-K 2023-01-18 BIOLASE, INC. DE 001-36385 87-0442441 27042 Towne Centre Drive Suite 270 Lake Forest CA 92610 949 361-1200 false false false false Common Stock, par value $0.001 per share BIOL NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports biol-20230118.htm biol-20230118.xsd biol-20230118_lab.xml biol-20230118_pre.xml biol-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "biol-20230118.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "biol-20230118.htm" ] }, "labelLink": { "local": [ "biol-20230118_lab.xml" ] }, "presentationLink": { "local": [ "biol-20230118_pre.xml" ] }, "schema": { "local": [ "biol-20230118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "biol", "nsuri": "http://www.biolase.com/20230118", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "biol-20230118.htm", "contextRef": "C_a766311a-126d-4948-b9e7-98fca401c6c9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "biol-20230118.htm", "contextRef": "C_a766311a-126d-4948-b9e7-98fca401c6c9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name", "verboseLabel": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "verboseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "verboseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "verboseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "verboseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biolase.com/20230118/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-000844-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-000844-xbrl.zip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end